🎗️
Breast Neoplasms
10 articles analyzed — Average score : 45/100
Grade distribution
Authors' conclusions
Articles
B
Mostly reliable (59/100)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. Positive
Hortobagyi GN et al.·The New England Journal of Medicine·Nov 2016
B
Mostly reliable (59/100)
Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. Negative
Miller AB et al.·BMJ·Feb 2014
B
Mostly reliable (58/100)
Palbociclib and Letrozole in Advanced Breast Cancer. Positive
Finn RS et al.·The New England Journal of Medicine·Jan 2016
C
Nuanced (50/100)
The benefits and harms of breast cancer screening: an independent review. Mixed
Marmot MG et al.·Lancet (London, England)·Oct 2012
C
Nuanced (48/100)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. Positive
Robson M et al.·The New England Journal of Medicine·Aug 2017
D
Unreliable (44/100)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Positive
Piccart-Gebhart MJ et al.·The New England journal of medicine·Oct 2005
D
Unreliable (40/100)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Mixed
Antoniou A et al.·American journal of human genetics·Apr 2003
D
Unreliable (32/100)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Positive
Cristofanilli M et al.·The New England Journal of Medicine·Aug 2004
D
Unreliable (30/100)
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. Positive
Hartmann LC et al.·The New England journal of medicine·Jan 1999
D
Unreliable (30/100)
Breast cancer and hormone-replacement therapy in the Million Women Study. Positive
Beral V & Beral V·Lancet·Aug 2003